Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough.

摘要: I disagree with conclusions outlined in the editorial by Drs. Weiner and Reich.1 The authors attempt wholesale importation of experiences bromocriptine into consideration non-ergot dopamine agonists, yet a 10-year follow-up ropinirole demonstrated very different results.2 also group disabilities long recognized as refractory to dopaminergic therapies overall assessments levodopa agonist efficacies. Furthermore, implicitly suggests an either/or scenario; one either uses agonists higher incidence side effects, or where evidence supports long-term motor complications.2 Unlike randomized clinical trials that necessitate dichotomous treatment arms resistance protocol variations, clinicians can exercise their judgment supplement replace needed. Provided adequate follow-up, there is no reason why prevalence, rather than incidence, effects subtherapeutic control should be any greater those initially treated compared initial levodopa. Unfortunately, converse cannot assured respect complications. The mention “levodopa phobia,” which pejoratively characterized associated …